Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 16/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11536617 | 0.85 | KMT2A (0.44) | KMT2ANR3C1PDE4BPOLBSLC22A12 | |
| SCHEMBL17963273 | 0.85 | NR3C1 (0.65) | NR3C1PDE4B | |
| SCHEMBL11544175 | 0.85 | KMT2A (0.74) | KMT2ANR3C1POLB | |
| SCHEMBL17963259 | 0.80 | NR3C1 (0.72) | NR3C1 | |
| SCHEMBL1471838 | 0.77 | POLB (0.61) | KMT2APDE4BPOLB | |
| SCHEMBL4930739 | 0.75 | KMT2A (0.34) | KMT2ANR3C1SLC22A12 | |
| SCHEMBL17963258 | 0.75 | NR3C1 (0.67) | KMT2ANR3C1 | |
| SCHEMBL11786333 | 0.74 | KMT2A (0.74) | KMT2ANR3C1POLB | |
| SCHEMBL582299 | 0.73 | NR3C1 (0.61) | KMT2ANR3C1PDE4B | |
| SCHEMBL11796115 | 0.72 | KMT2A (0.57) | KMT2ANR3C1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915286-B2 | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-29 | — | — | US | disclosed |
| US-20100022571-A1 | SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-28 | — | — | US | disclosed |
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
| EP-1934219-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007031838-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022571-A1 | SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | PDE4B, PDE4A, PDE3B | KMT2A 2941/4885NR3C1 3791/4885PDE4B 1/4885 |
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4B, PDE3A | KMT2A 2949/4885NR3C1 3658/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.